About David Lucchino
David Lucchino's career is firmly rooted in the world's most important life sciences cluster–Kendall Square in Cambridge, MA. David is Chairman and CEO of Frequency Therapeutics, which he co-founded with MIT Institute Professor Robert S. Langer, and Jeffrey Karp, Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. David is Vice Chairman of MassBio, the state's leading trade association for life sciences. He is a trustee and Chair of the Audit Committee of Mt. Auburn Hospital, a Harvard Medical School facility; a trustee at Babson College; and a board member at the Multiple Myeloma Research Foundation.
Find out more
About This Idea
Frequency Therapeutics is a biotechnology company developing and commercializing its innovative platform technology to address a substantial and unmet clinical need–hearing loss. The company's platform technology is based on discoveries in stem cell biology and has has shown great promise in reversing sensory hearing loss, a malady that impacts over 1 billion people globally and which currently has no therapeutic solution.
Find out more
Frequency Therapeutics was co-founded by two world-renowned scientists: MIT Institute Professor Robert S. Langer and Jeffrey Karp, Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. Frequency is translating ground breaking discoveries made in the area of cell programming. They've solved a key bottleneck in bringing stem cell programming to patients–namely by harnessing rapidly translatable small molecule combinations that selectively target entrenched stem cells in the body.
Early Bird Registration Rate Ends: